Effect of Plant-Derived n-3 Polyunsaturated Fatty Acids on Blood Lipids and Gut Microbiota: A Double-Blind Randomized Controlled Trial

Hongjie Liu, Xiaoqin Li, Yalun Zhu, Yue Huang, Qin Zhang, Shan Lin, Can Fang, Linyan Li, Yanling Lv, Wenhua Mei, Xiaolin Peng, Jiawei Yin, Liegang LiuFrontiers in Nutrition 2022 · DOI

TL;DR

This study investigated the impact of plant-derived omega-3 fatty acids (PUFAs) on blood lipids and gut microbiota in individuals with marginal hyperlipidemia. The 12-week intervention with plant-derived n-3 PUFAs significantly reduced total cholesterol and favorably altered the gut microbiome by decreasing the Firmicutes to Bacteroidetes ratio, suggesting potential benefits for cardiovascular health and intestinal well-being.

What Problem Does This Paper Address?

Hyperlipidemia, a condition characterized by elevated levels of lipids in the blood, is a significant risk factor for heart disease and stroke. While omega-3 polyunsaturated fatty acids (PUFAs), particularly those from marine sources, are known for their cardioprotective effects, the role of plant-derived n-3 PUFAs remains less clear and somewhat controversial regarding their impact on blood lipid profiles. Furthermore, the influence of these plant-based omega-3s on the human gut microbiota, a complex ecosystem increasingly recognized for its role in metabolic health, is largely unexplored. This paper aims to bridge this knowledge gap by conducting a rigorous randomized controlled trial to assess the effects of plant-derived n-3 PUFAs on both blood lipids and gut microbial composition in individuals with marginal hyperlipidemia.

Methods

The study employed a double-blind, randomized controlled trial design. Seventy-five participants diagnosed with marginal hyperlipidemia were randomly assigned to either an intervention group receiving plant-derived n-3 PUFA-enriched oil capsules or a control group receiving corn oil capsules. The intervention lasted for 12 weeks.

Key measurements included:

  • Primary Outcome: Changes in serum lipid levels (total cholesterol, triglycerides, LDL-C, HDL-C).
  • Secondary Outcomes: Changes in gut microbiota composition and fecal short-chain fatty acids (SCFAs).

Gut microbiota analysis was performed using 16S ribosomal RNA (rRNA) gene sequencing of fecal samples. Statistical analysis involved mixed-effects models to assess treatment effects over time, with both intent-to-treat (ITT) and per-protocol (PP) analyses conducted for primary outcomes. For secondary outcomes, only PP analysis was performed on participants who provided fecal samples.

Datasets

The study utilized data collected from 75 participants with marginal hyperlipidemia. Fecal samples were collected at baseline, week 6, and week 12 for 16S rRNA gene sequencing. Blood samples were also collected for lipid profile analysis. No new public datasets were introduced; the study relied on data collected from its participants.

Key Insights and Ideas

  • Plant-based Omega-3s are Effective for Total Cholesterol: The study provides strong evidence that plant-derived n-3 PUFAs can effectively lower total cholesterol (TC) levels, even in individuals with only marginal hyperlipidemia. This is a crucial finding, as it highlights the potential of plant-based sources to contribute to cardiovascular health management.
  • Favorable Gut Microbiota Shifts: The intervention led to a significant increase in the relative abundance of Bacteroidetes and a decrease in the Firmicutes to Bacteroidetes (F/B) ratio. This shift is particularly interesting because a high F/B ratio is often associated with metabolic disorders like obesity and hyperlipidemia, suggesting that plant-derived n-3 PUFAs may help restore a healthier gut microbial balance.
  • Specific Bacterial Genus Modulation: At the genus level, the study observed a significant decrease in the abundance of Phascolarctobacterium and Veillonella in the intervention group. These bacteria have been previously linked to higher blood lipid levels and inflammation, further supporting the beneficial impact of the n-3 PUFA intervention on gut health.
  • Potential for Improved Intestinal Health: The observed changes in the gut microbiota, particularly the reduced F/B ratio and the decrease in potentially pro-inflammatory bacteria, suggest that plant-derived n-3 PUFAs may confer advantageous consequences for intestinal health, beyond just lipid metabolism.

Key Results

  • Total Cholesterol Reduction: The n-3 PUFA supplementation group showed a significant reduction in total cholesterol (TC) by -0.43 mmol/L (95% CI -0.84 to -0.01 mmol/L, P < 0.05) compared to the control group.
  • Gut Microbiota Shift: The relative abundance of Bacteroidetes significantly increased in the intervention group (P < 0.01; FDR corrected p = 0.11).
  • F/B Ratio Decrease: The ratio between Firmicutes and Bacteroidetes (F/B ratio) significantly decreased in the intervention group (P < 0.05; FDR corrected p = 0.16).
  • Genus-Level Changes: Phascolarctobacterium and Veillonella showed a significant decrease in relative abundance in the intervention group (P < 0.01; FDR corrected p = 0.18 for both).
  • No Significant Changes in Other Lipids or SCFAs: While trends were observed, there were no statistically significant differences in triglycerides (TG), LDL-C, or HDL-C between groups. Fecal SCFA concentrations also did not differ significantly.

Limitations and Future Work

The authors acknowledge several limitations:

  • Intervention Duration: The 12-week intervention period might be too short to fully capture the long-term effects of n-3 PUFA supplementation on gut microbiota and their metabolites.
  • Dropout Rates: The study experienced a moderately high dropout rate, which could introduce confounding and selection bias. However, the ITT and PP analyses yielded similar significant findings, mitigating some of this concern.
  • Comparison with Healthy Individuals: The study did not compare the gut microbiota changes to those in healthy individuals, making it difficult to definitively determine if the observed alterations were solely ameliorating a disturbance caused by hyperlipidemia.

Future research could focus on longer intervention periods to assess sustained effects, explore the impact of different dosages of plant-derived n-3 PUFAs, and investigate the specific mechanisms by which these fatty acids influence gut microbial composition and function. Further studies could also explore the interplay between plant-derived n-3 PUFAs, gut microbiota, and other metabolic pathways.

Summary updated

Abstract

Our results demonstrated that plant-derived n-3 PUFAs beneficially affected the serum levels of TC and decreased the ratio between <i>Firmicutes</i> and <i>Bacteroidetes</i> during the 12-week intervention period, which might confer advantageous consequences for lipid metabolism and intestinal health.
BibTeX
@inproceedings{liu2022effect,
  author = {Hongjie Liu and Xiaoqin Li and Yalun Zhu and Yue Huang and Qin Zhang and Shan Lin and Can Fang and Linyan Li and Yanling Lv and Wenhua Mei and Xiaolin Peng and Jiawei Yin and Liegang Liu},
  title = {{Effect of Plant-Derived n-3 Polyunsaturated Fatty Acids on Blood Lipids and Gut Microbiota: A Double-Blind Randomized Controlled Trial}},
  booktitle = {Frontiers in Nutrition},
  year = {2022},
  doi = {10.3389/fnut.2022.830960},
}
Figure